… melanoma cohort of the Phase I study of IMCgp100, a recombinant T-cell receptor that recognizes
the melanoma … , also showed early promising results with 3 patients (20%) achieving a …

… plus paclitaxel or gemcitabine plus treosulfan; patients with advanced … (cSCC) received
carboplatin, cisplatin, paclitaxel, or … In CLL patients, the cumulative recurrence rate of cSCC at 8 …

… , treosulfan and cisplatin, in association with gemcitabine. … patients with inoperable stage
III or stage IV melanoma of … in 32 patients with recurrent or metastatic UM in a phase II study, …

… For brachytherapy, reported local recurrence rates are 14.7%—for 106Ru treatment, 7%–10…
drug was stopped after the first dose due to the onset of a severe form of diabetes (grade 4). …

… included recurrent grade 3 proteinuria, grade 4 … The median OS was worst in patients
receiving treosulfan/gemcitabine as … The combination therapy of treosulfan/gemcitabine was well …

… A randomized phase II study in China evaluated observation … with temozolomide and cisplatin
in patients with stage I/II MM … late relapses can occur, with 20% to 30% of patients dying of …

… -γ-adenovirus in cutaneous metastatic melanoma is ongoing [… treosulfan or cisplatin,
gemcitabine and treosulfan, cisplatin, … in a small group of patients relapsing after complete first …

… 4 antibodies shall be considered. In particular scenarios for patients with stage IV melanoma
… that despite a slight increase in recurrence-free survival in patients undergoing SLNB, it has …

… While the ability to identify patients at high risk of recurrence … The combination of treosulfan
and gemcitabine in metastatic … of cisplatin, vindesine, and dacarbazine had seemed in phase …

… For instance, the median OS for the triplet drug combination of cisplatin, treosulfan and
gemcitabine was 6 months only in relapsed UM (Atzpodien et al., 2008). Radioembolisation with …